Arch Biopartners Expands Clinical Trial for AKI Treatment
Arch Biopartners Inc. continues to enhance its impact in the medical field with the recent expansion of its Phase II trial focusing on cardiac surgery-associated acute kidney injury (CS-AKI). This trial will now include participation from Royal Columbian Hospital (RCH), fostering broader access to potential treatments for patients impacted by this serious condition.
Key Developments in the Clinical Trial
Yesterday, the Fraser Health Research Ethics Board granted the necessary approval for RCH to join the ongoing trial evaluating the LSALT peptide, a promising therapeutic candidate aimed at preventing and treating AKI in patients undergoing cardiac surgery. This expansion marks another significant step in the efforts of Arch Biopartners to confront the substantial challenges presented by kidney injuries.
Operational Preparations
With the green light from the ethics board, the clinical team at RCH in New Westminster is set to finalize operational approvals and commence training sessions. This hospital will serve as the eighth site involved in the global study and is anticipated to be the fourth site actively recruiting patients across Canada.
Current Enrollment Status
The clinical team at the University Health Network’s Toronto General Hospital and University of Calgary’s Cumming School of Medicine are actively enrolling patients into this critical trial. Meanwhile, Unity Health’s St. Michael’s Hospital is preparing for its participation, pending final authorization from Clinical Trials Ontario, and the Arch team is diligently seeking additional sites in both Canada and the United States to widen the trial's scope.
Strategic Company Moves
In addition to the trial expansion, Arch Biopartners has recently secured final approval from the TSX Venture Exchange for its acquisition of Lipdro Therapeutics Inc. This acquisition includes 250,000 common shares of Arch in addition to royalty agreements tied to the net sales of drug candidates focusing on chronic kidney disease (CKD). This strategic move is expected to enhance Arch's capacities in developing treatments targeting IL-32.
Stock Options for Management
Further underpinning its commitment to sustainable growth, Arch's Board of Directors has approved the issuance of 750,000 stock options to directors and officers. These options, granted for remuneration purposes, can be exercised at a price of $1.70 per share over a decade, effective from November 4, 2025, and are contingent upon obtaining requisite regulatory approvals.
About Arch Biopartners
Arch Biopartners Inc. stands at the forefront of therapeutic biotechnology, concentrating on the development of innovative drugs aimed at treating acute and chronic kidney diseases. The company is committed to advancing an integrated program that not only explores new treatments but effectively addresses kidney injuries induced by inflammation and detrimental toxins.
Pipeline Overview
Arch's development pipeline demonstrates diverse efforts to meet the critical needs in kidney care. This includes:
- LSALT peptide: A Phase II clinical program specifically designed for CS-AKI.
- Cilastatin: A repurposed candidate undergoing a Phase II trial aimed at preventing toxin-induced AKI.
- CKD Therapeutics: A promising preclinical program dedicated to chronic kidney disease.
These initiatives present distinct, mechanism-based approaches to addressing common causes of kidney damage, potentially revolutionizing the treatment landscape for millions suffering from kidney-related ailments globally.
Connect with Arch Biopartners
For more insights about the company’s scientific advancements and clinical trials, explore Arch's dedicated resources. You can also follow the company on LinkedIn, Bluesky, and X (formerly Twitter) for updates and industry news.
Frequently Asked Questions
What is the Phase II trial about?
The Phase II trial focuses on evaluating the LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
Where will the trial take place?
The trial will include various sites with Royal Columbian Hospital being the newest addition to the global study.
What other hospitals are involved in the trial?
Other participating hospitals include Toronto General Hospital and the University of Calgary, among others.
What is the significance of the Lipdro acquisition?
This acquisition aims to strengthen Arch’s capabilities in developing drug candidates for chronic kidney disease.
Who can I contact for more information?
Aaron Benson, the Director of Communications at Arch Biopartners Inc. is available for inquiries regarding the company and its projects.
